Program
silodosin
Also written as “Silodosin”, “KSO-0400” and “Silodosin Capsules”.
Its studies are mostly in Prostatic Hyperplasia · Nocturia · Lower Urinary Tract Symptoms · Ureteral Calculi · Ureterolithiasis, led by 6 companies.
Drug pageSilodosin: every studyMany companies study it; this page follows only the 17 they lead. All 40 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 60 open or running | phase 3since Sep 14, 2005 | Sep 14, 2005 | none ahead |
| JW Pharmaceuticalits history only | 50 open or running | phase 4since Oct 25, 2010 | Oct 25, 2010 | none ahead |
| Kissei Pharmaceuticalits history only | 20 open or running | phase 2since Oct 15, 2010 | Oct 15, 2010 | none ahead |
| RECORDATI GROUPits history only | 20 open or running | phase 4since Dec 21, 2012 | Aug 2, 2006 | none ahead |
| Shanghai Huilun Pharmaceuticalits history only | 10 open or running | phase 4since Aug 14, 2025 | Aug 14, 2025 | none ahead |
| Xintian Pharmaceuticalits history only | 10 open or running | phase 4since Sep 19, 2022 | Sep 19, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2005First studies: 3 phase 3 studies in Prostatic HyperplasiaFirst studyNCT00224133, NCT00224120, NCT00224107
- Aug 21, 2008Phase 2 study in ProstatitisNCT00740779 · 153 enrolled · United States
- Nov 17, 2008Phase 2 study in NocturiaNCT00793819 · 215 enrolled · United States
- Jun 14, 2010Phase 2 study in Ureteral CalculiNCT01144949 · 239 enrolled · United States
TargetBeta
“Alpha-1a adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on ADRA1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 60 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 6 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01144949Ureteral Calculi · United States | 2 | Completed | Jul 2012 | 239 |
| NCT00793819Nocturia · United States | 2 | Completed | Oct 2009 | 215 |
| NCT00740779Prostatitis · United States | 2 | Completed | Oct 2009 | 153 |
| NCT00224133Prostatic Hyperplasia · United States | 3 | Completed | Apr 2007 | 661 |
| NCT00224120Prostatic Hyperplasia · United States | 3 | Completed | May 2006 | 462 |
| NCT00224107Prostatic Hyperplasia · United States | 3 | Completed | Aug 2006 | 461 |
How it is read
Names in the registry
- “Silodosin”, 12 entries
- “silodosin”, 5 entries
- “KSO-0400”, 2 entries
- “Silodosin Capsules”, 1 entry
- “Silodosin 8 mg”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 9 studies
- Nocturia, 2 studies
- Lower Urinary Tract Symptoms, 1 study
- Ureteral Calculi, 1 study
- Ureterolithiasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.